Supplementary Figure S1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Mark Yarchoan; John D. Powderly; Bruno R. Bastos; Thomas B. Karasic; Oxana Crysler; Pamela N. Münster; Meredith McKean; Leisha A. Emens; Yvonne M. Saenger; Yasser Ged; Robert Stagg; Steven Smith; Chan C. Whiting; Anne Moon; Peppi Prasit; Yonchu Jenkins; Nathan Standifer; Thomas W. Dubensky; Sam H. Whiting; Susanna V. Ulahannan

doi:10.1158/2767-9764.25639251.v1

Abstract

Relationship between dose (mg BID) and AUC0-24 of TPST-1120 at steady state on Cycle 1 Day 8. Monotherapy and nivolumab combination data points offset slightly for clarity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yarchoan et al. (2024) studied this question.

synapsesocial.com/papers/68e6e9a7b6db643587664bee https://doi.org/10.1158/2767-9764.25639251.v1

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Abstract

Discussion

Cite This Study

Keep reading

Keep reading